Fed. Circ. Won't Eye Novartis Case Flipped By Judge Change
The full Federal Circuit said Tuesday it won't review a decision in which a split panel initially upheld Novartis' patent on multibillion-dollar multiple sclerosis drug Gilenya, then invalidated it after a...To view the full article, register now.
Already a subscriber? Click here to view full article